If you've been told you have prediabetes, you may have seen headlines about tirzepatide and a study lasting more than three years. The findings were encouraging for the people studied, but the headline alone doesn't explain who took part or what happened after treatment stopped.
The research followed a group of adults with prediabetes who also had obesity or overweight with a weight-related condition. It compared tirzepatide with a placebo, an inactive treatment used as a comparison. Here's what that design can—and can't—tell us.
The people in the longer study
The larger SURMOUNT-1 study enrolled 2,539 adults. Among them, 1,032 had prediabetes at the beginning and were the focus of the longer analysis. Prediabetes means blood glucose is higher than normal but not high enough to meet the criteria for type 2 diabetes. It doesn't mean that diabetes is inevitable.
Participants were randomly assigned to weekly tirzepatide at one of three study doses or to a placebo. The planned treatment period lasted 176 weeks, followed by 17 weeks without the assigned treatment. Participants also received lifestyle counseling.
The study was designed around a particular group. Results for adults with prediabetes in this trial should not automatically be applied to people who already have diabetes or to someone whose circumstances are quite different. Some participants also stopped treatment or left the study, which is part of the context for interpreting long-term findings.
What happened to weight?
At the end of the 176-week treatment period, the tirzepatide groups had greater average weight reductions than the placebo group. Results differed by the dose assigned in the study, and participants' individual experiences varied.
An average can describe a group without describing a single person in that group. It doesn't tell you how quickly you would lose weight, whether you would tolerate a medicine, or what your weight would be after three years. The trial doses were part of a research protocol; they aren't instructions for starting or changing treatment.
Researchers also followed participants for a short period after the assigned treatment ended. Weight regain was observed in the groups that had received tirzepatide during that off-treatment period. Seventeen weeks gives some information about what happened next, but it doesn't establish exactly what would happen to every person over the following years.
What did the study find about diabetes?
By week 176, type 2 diabetes had been identified in 10 of the 762 participants assigned to tirzepatide across the three dose groups, compared with 36 of the 270 participants assigned to placebo. Those figures are about 1.3% and 13.3%, respectively, in the reported analysis.
That's a meaningful difference in this study. It is also specific to the participants, treatment period, and way the researchers analyzed the results. It does not mean an individual has a zero risk of developing diabetes, or that the result will last forever after treatment ends.
The researchers checked again after the off-treatment period. Additional diagnoses occurred, including among people previously assigned tirzepatide, although the reported proportion remained lower than in the placebo group at that point. The follow-up doesn't answer what happens indefinitely after stopping.
Side effects were part of the picture
The most common reported adverse events, apart from COVID-19, were digestive symptoms. Many were mild or moderate and appeared particularly while doses were being increased. As with the weight and diabetes results, group reporting can't predict how an individual will feel.
If you are discussing any weight-management medicine, ask what symptoms to watch for, whom to contact, and what to do if eating or drinking becomes difficult. A treatment that looks promising in a study still has to be suitable and manageable for the person taking it.
A few reasons to read the result carefully
This was a randomized comparison with a placebo and a longer follow-up than many weight-management studies. Those features make it useful. There are also limits: people who stopped treatment early were not all followed in the same way through the extension, and some left before the end. Missing information and different follow-up can affect how confidently results apply outside the trial.
The trial was funded by the company that makes tirzepatide. Funding is worth considering alongside the study's methods and other evidence; it isn't, by itself, a reason to accept or dismiss a result.
Most of all, the study doesn't make one treatment the right choice for everyone with prediabetes. Your other health conditions, preferences, medication history, coverage, and goals belong in that conversation.
Bring the question to your own appointment
If you're curious whether the findings relate to you, ask: “How was my prediabetes identified?” “What follow-up do you recommend?” and “Would weight-management treatment be useful for my situation?” You can also ask what other approaches fit your health and what you would monitor together over time.
The three-year analysis found fewer new type 2 diabetes diagnoses in the tirzepatide groups during the study. It gives clinicians and patients another piece of evidence to discuss, not a guarantee about any one person's future.










